Clinical-stage drug development company Syntara (ASX:SNT), formerly Pharmaxis, has commenced dosing in the final cohort of a phase 2 clinical trial studying its pan-LOX inhibitor SNT-5505 in patients with myelofibrosis. …
Syntara commences dosing in phase 2 myelofibrosis trial of its pan-LOX inhibitor
December 13, 2023 Australian Biotech
Latest Video
New Stories
-
Former Speaker of the House appointed as official Patron of Rare Cancers Australia
March 25, 2025 - - Latest News -
Another day, and another addition to what is now a motherload of bad ideas
March 25, 2025 - - Latest News -
Australian eye therapy company now focused on survival after clinical trial result
March 25, 2025 - - Latest News -
Mark Butler: Patients waiting too long and 'as the Health Minister, of course, I am sorry for that'
March 24, 2025 - - Latest News -
What happens to the conspiracy when the industry and ministerial criticisms sound remarkably similar?
March 24, 2025 - - Latest News -
Nanotechnology could improve odds in treating aggressive breast cancers
March 24, 2025 - - Latest News -
Call for safety net change with half a million Australians missing out on cheaper medicines
March 24, 2025 - - Latest News